Gryphon Digital Mining Inc Warrants (17/06/2024) Stock (OTC: KERNW)

Gryphon Digital Mining Inc Warrants (17/06/2024) (OTC:KERNW) Stock, Quote.Headers.trade-ideas

Gryphon Digital Mining Inc Warrants (17/06/2024)

WIIM

SQFT

Presidio Property Trust shares are trading higher after the company announced it was granted an additional 180-day period to regain compliance.

Tharimmune, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THAR#NASDAQ">THAR</a>) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company committed to pioneering therapies in immunology and inflammation, today announced it has entered into a securities purchase agreement to raise gross proceeds of approximately $2.02 million through a private placement.
The agreement includes the issuance of 961,446 shares of common stock (or common stock equivalents) and warrants to purchase up to an additional 480,723 shares of common stock. Each share (or common stock equivalent) is priced at $2.10 and is accompanied by a warrant. The warrants will have an exercise price of $2.031 per share, becoming exercisable six months after issuance and expiring five and one-half years from the date of issuance. The closing of this transaction is expected on or about December 9, 2024, subject to customary closing conditions.

News

Offerings

THAR

Tharimmune Has Entered Into A Securities Purchase Agreement To Raise ~$2.02M Through A Private Placement, To Advance Development Programs

Dividends

MORN

Morningstar Increases Quarterly Dividend From $0.405 To $0.455 Per Share

The long-awaited hearing to discuss <a href="https://www.benzinga.com/topic/cannabis-rescheduling">cannabis rescheduling</a> will begin on January 21, 2025, marking a significant moment in the ongoing debate over cannabis regulation. As Business of Cannabis <a href="https://businessofcannabis.com/cannabis-rescheduling-hearing-set-to-begin-on-january-21-for-6-weeks-as-frustrations-over-process-continue-to-build/">reported</a>, the six-week hearing will continue until March 6, 2025, but its outcome remains uncertain due to political and procedural challenges.
With key positions in the new administration still unconfirmed, many questions remain about how much influence the incoming cabinet will have on the hearings. This uncertainty has raised concerns over the DEA&#8217;s impartiality and the fairness of the process.
<h3 class="wp-block-heading">Legal Challenges From Health Coalitions And Advocates</h3>
In a move that has added to the controversy, the Doctors for Drug Policy Reform has filed a federal court petition challenging the DEA's exclusion from the hearings. According to Businnes of Cannabis, the group argues that their medical expertise is essential for evaluating the implications of cannabis rescheduling, particularly regarding medical marijuana prescriptions.
Additionally, weeks ago, the agency <a href="https://www.benzinga.com/markets/cannabis/24/11/42169153/dea-judge-blocks-researchers-motion-in-cannabis-rescheduling-case">denied MedPharm's bid to join the December 2 hearing</a>. MedPharm, a DEA-registered research firm, criticized the exclusion of marijuana researchers and the inclusion of prohibitionist organizations such as Smart Approaches to Marijuana (SAM).&nbsp;
SAM has been also at the center of the controversy. On November 28, attorney Matt Zorn <a href="https://www.benzinga.com/24/12/42274698/dea-sued-for-allegedly-hiding-emails-with-anti-marijuana-group">sued the DEA</a> for failing to release records related to its communications with the organization. The DEA dismissed them as "gossip," arguing that there was no illegal contact, despite SAM President Kevin Sabet admitting to discussing the details of the rescheduling with DEA insiders. <a href="https://www.benzinga.com/government/regulations/24/11/42198793/prohibitionist-group-denies-collusion-allegations-ahead-of-dea-cannabis-rescheduling-hearing">SAM also denied</a> that the conversations had anything to do with the rescheduling procedure.
Earlier in November, the Veterans Action Council, a cannabis advocacy organization for military veterans, <a href="https://www.benzinga.com/news/legal/24/11/42068859/veterans-group-challenges-dea-for-seat-at-cannabis-debate-table">filed a petition</a> challenging its exclusion from the DEA&#8217;s participant list, published in October. The petiton followed the withdrawal of some designated participants and growing scrutiny over the agency's handling of the rescheduling process.
Several organizations have pulled out of the hearings since the initial announcement. The American College of Occupational and Environmental Medicine missed important procedural deadlines, while an oncologist representing the American Academy of Hospice and Palliative Medicine opted not to participate. Additionally, five remaining participants are represented by David Evans, a prominent anti-cannabis advocate, highlighting the polarized nature of the upcoming hearings.
<h3 class="wp-block-heading">Scheduled Presentations And Participants</h3>
The DEA has outlined a strict schedule for the hearings, featuring presentations from various stakeholders, including industry groups, law enforcement and medical professionals. Notable participants include the National Cannabis Industry Association and Smart Approaches to Marijuana, among others. The schedule includes:
<ul>
<li>January 21: Presentation by the government</li>
<li>January 22-23: Presentations from Hemp for Victory, Cannabis Bioscience International Holdings and other groups</li>
<li>January 28-30: Presentations from the Connecticut Office of the Cannabis Ombudsman, National Cannabis Industry Association and additional participants</li>
<li>February 4-6: Presentations from The Commonwealth Project, Veterans Initiative 22 and others</li>
<li>February 18-20: Presentations from the Tennessee Bureau of Investigation, International Association of Chiefs of Police and more</li>
<li>February 25-27: Presentations from Smart Approaches to Marijuana, Community Anti-Drug Coalitions of America and other stakeholders</li>
<li>March 4-6: Presentations from Dr. Kenneth Finn, National Drug and Alcohol Screening Association and others.</li>
</ul>
<h3 class="wp-block-heading">Public Comments Excluded From the Process</h3>
Although more than <a href="http://v">43,000 public comments were submitted</a> during the 60-day comment period, the DEA has ruled that these comments will not be accepted as evidence, citing the limitations of the Administrative Procedure Act. This decision has generated criticism from cannabis advocates and industry leaders.
<h3 class="wp-block-heading">High Stakes For The Industry</h3>
Reclassifying marijuana could provide <a href="https://www.benzinga.com/markets/cannabis/24/05/38901900/what-schedule-iii-really-means-for-cannabis-industry-and-consumers-congressional-experts-explain">significant advantages to the U.S. cannabis industry</a>. It would ease research and financial restrictions, improve access to banking and reduce legal challenges, enabling businesses to operate more freely. A Schedule III classification could also lead to broader insurance coverage and more federal funding for cannabis research, potentially fostering growth, investment and innovation. Advocates argue that rescheduling would enhance regulation and increase access to medical cannabis, but given the complexities of the process, the final decision may still be months away, with lasting impacts on the industry.
Cover image made with AI

Cannabis

Government

Politics

DEA's Cannabis Rescheduling Hearing Set To Begin In January 2025 As Controversy Mounts

The U.S. stock market posted another week of strong performance, with major large-cap indices such as the S&amp;P 500, the Dow Jones and the Nasdaq 100 <a href="https://www.benzinga.com/general/social-media/24/12/42371493/tech-stocks-rise-meta-rallies-as-court-upholds-tiktok-ban-bitcoin-roars-above-101000-whats-driving-markets-friday">extending their record highs.</a>
Technology and consumer discretionary sectors led the gains, driven by several mega-cap tech giants – Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) and Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) – hitting new peaks.
In November, the U.S. labor market showed robust signs of recovery, with nonfarm payrolls rising by 227,000, up sharply from an upwardly revised 36,000 in October and above expectations of 220,000. The unemployment rate inched up to 4.2%, as expected, while average hourly <a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42363278/us-economy-adds-227000-jobs-in-november-wage-growth-accelerates">earnings slightly exceeded forecasts.</a>
The University of Michigan&#8217;s consumer sentiment index revealed the most favorable overall conditions in seven months, bolstered by a significant rise in the current economic conditions subindex. Yet, the survey also highlighted growing concerns over inflation, with short-term inflation expectations rising. A relevant share of consumers reported advancing purchases of durable goods due to fears of accelerating <a href="https://www.benzinga.com/news/econ-s/24/12/42366245/consumer-sentiment-hits-7-month-high-but-inflation-fears-divide-democrats-republicans">inflation in the future.</a>
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) dominated economic and financial headlines, surging above $100,000 for the first time ever on Wednesday.
<h2 class="wp-block-heading">What You Might Have Missed</h2>
<h3 class="wp-block-heading">Stellantis CEO Departs</h3>
Stellantis N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STLA#NYSE">STLA</a>)' Carlos Tavares exited, intensifying market concerns after a 50% value drop in 2024. Leadership uncertainty now threatens recovery, with analysts warning of escalating challenges in a highly <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42273230/stellantis-market-value-halves-in-2024-why-ceo-tavares-exit-could-take-things-from-bad-to-worse">competitive automotive industry landscape.</a>
<h3 class="wp-block-heading">Bitcoin Caution Advised</h3>
A veteran trader urged caution on aggressive Bitcoin and equity longs amid rising market volatility. The warning highlights the importance of prudent risk management and strategic positioning in <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42359217/veteran-trader-warns-against-aggressive-long-positions-on-bitcoin-equities-amid-market-volatility">an unpredictable cryptocurrency landscape.</a>
<h3 class="wp-block-heading">Top Santa Stocks</h3>
There are 10 S&amp;P 500 stocks that historically excel in December's second half. These consistent performers leverage the Santa Rally effect, presenting investors with strong year-end opportunities <a href="https://www.benzinga.com/24/12/42352997/santa-rally-here-are-10-sp-500-stocks-that-historically-outperformed-in-decembers-second-half">for potential portfolio growth.</a>
<h3 class="wp-block-heading">Prominent Trader Drops Tesla Short</h3>
A prominent trader exited his Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) short position, citing a shift in fundamentals and Elon Musk's evolving relationship with President-elect Donald Trump. Tesla shares are up 41% year-to-date, <a href="https://www.benzinga.com/24/12/42311290/trader-danny-moses-says-he-is-no-longer-shorting-tesla">with analysts growing bullish.</a>
<h3 class="wp-block-heading">Powell On Bitcoin</h3>
Fed Chair Jerome Powell likened Bitcoin to gold, describing it as virtual and digital. His remarks underline Bitcoin's growing status as a speculative asset and a store of value in <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42325788/fed-chair-powell-bitcoin-is-like-gold-just-virtual-and-digital">the evolving financial ecosystem.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42368380/economists-react">Strong November Jobs Report Could Signal Slower Interest Rate Cuts Ahead, Experts Say</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Analyst Color

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Equities

Large Cap

Eurozone

Economics

Federal Reserve

Tech

$BTC

AMZN

STLA

TSLA

Stock Markets Extends Record Highs, US Labor Market Recovers, Bitcoin Hits $100,000: This Week In The Markets

Presidio Property Trust, Inc. ("Presidio" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SQFT#NASDAQ">SQFT</a>, SQFTP, SQFTW))), an internally managed, diversified real estate investment trust ("REIT"), today announced that the Company has been granted an additional 180-day period from Nasdaq's Listing Qualification Department, through June 2, 2025, to regain compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market. The Company's common stock continues to trade on the Nasdaq Capital Market under the symbol "SQFT."

Presidio Granted Second 180-Day Period By Nasdaq's Listing Qualification Department Through June 2, 2025, To Regain Compliance With Minimum Bid Price Rule

CARR

Carrier Global Increases Quarterly Dividend From $0.19 To $0.225

RAIL

FreightCar America Receives Nasdaq Notification For Non-Compliance With Compensation Committee Charter Requirements

W. R. Berkley Corporation (NYSE:<a href="https://www.benzinga.com/stock/WRB#NYSE">WRB</a>) announced today that its Board of Directors declared a special cash dividend on its common stock of 50 cents per share to be paid on December 27,2024 to stockholders of record at the close of business on December 16, 2024. The special dividend announced today is the third in 2024.
In addition, the Board of Directors has declared a regular quarterly cash dividend on its common stock of 8 cents per share to be paid on December 27,2024 to stockholders of record at the close of business on December 16, 2024.
Including the dividends announced today, the special and regular quarterly cash dividends paid year-to-date, and shares repurchased through September 30, 2024, total capital returned to shareholders during 2024 is approximately $768.2 million.

W. R. Berkley Declares Special Dividend Of $0.50 Per Share To Be Paid On December 27, 2024

Insider Trades

Dyne Therapeutics Director Kersten Dirk Sells 138,845 Shares At An Average Price Of $29.38 Per Share

Biotech

General

VINC

Vincerx Pharma Announces Strategic Plan To Advance Phase 1 VIP943 Study, Implements 55% Workforce Reduction, Explores Strategic Alternatives Including Licensing, Mergers, And Asset Sales; Expects $0.3M-$0.6M In Severance-Related Costs Through Early 2025

Stock Split

CVLG

Covenant Logistics Group Announces 2-For-1 Stock Split, Will Be Effected By Means Of A Stock Dividend To The Holders Of Record Of Covenant's Class A Common Stock And Class B Common Stock As Of The Close Of Business On December 20, 2024

BLMZ

BloomZ Receives Nasdaq Notification For Non-Compliance With Minimum Bid Price Rule

Freight Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRGT#NASDAQ">FRGT</a>, "Fr8Tech" or the "Company"))), a logistics management innovation company, offering a diverse portfolio of technology-driven solutions that address distinct challenges within the supply chain ecosystem, today announced updates to its public filing procedures.
On December 4, 2024, Freight Technologies, Inc. (the "Company") determined that it no longer satisfied the definition of "foreign private issuer" under the rules and regulations of the U.S. Securities and Exchange Commission ("SEC"). As a result, the Company has begun filing Current Reports on Form 8-K with the SEC as if it were a fully domestic U.S. company, and will commence filing Quarterly Reports on Form 10-Q (beginning with the period ending March 31, 2024) and Annual Reports on Form 10-K (beginning with the annual report for fiscal year 2024), as well as proxy statements with respect to meetings of shareholders.

FRGT

Freight Technologies Provides Update On Its Public Filings Procedures; Announces Change From Foreign Private Issuer, Begins Filing Form 8-K, 10-Q, 10-K As U.S. Domestic Company

DRMA

Dermata Therapeutics shares are trading higher after the company received a notice of allowance for a U.S. patent titled "COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN CONDITIONS (INCLUDING ACNE)"

IFBD

Infobird Signs Equity Acquisition Agreement To Acquire 32% Of Pure Tech Global Limited For $25.7M, Funded By $19.8M Cash And $5.9M Convertible Promissory Note, With Closing Expected By January 2025

Management

RBOT

Vicarious Surgical CFO William Kelly Departs

Data from nine abstracts to be presented, including first data from the EpiCom Trial, a prospective evaluation of behavioral outcomes in patients with tuberous sclerosis complex, which suggests improvements in severity of behavioral symptoms
Real-world data from the BECOME (BEhavior, COgnition and More with Epidiolex&#xAE;)&nbsp;surveys, which show outcomes reported by long-term care facility nurses and tuberous sclerosis complex caregivers
For U.S. media and investors only
DUBLIN, Dec. 6, 2024 /PRNewswire/ --&nbsp;Jazz Pharmaceuticals plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) today announced nine company-sponsored Epidiolex&#xAE;&nbsp;(cannabidiol) posters are being presented at the American Epilepsy Society (AES) 2024 Annual Meeting, being held December 6-10 in Los Angeles, California.
Data presented at the meeting includes updated analyses of real-world data from the BECOME-TSC (BEhavior, COgnition, and More with Epidiolex) caregiver survey, which characterizes and quantifies seizure and non-seizure outcomes in patients with epilepsy and tuberous sclerosis complex (TSC) treated with&nbsp;Epidiolex. An additional presentation showcases data from the BECOME-LTC survey, which evaluated the perspectives of nurses who care for patients with epilepsy in long-term care (LTC) facilities and group homes, reporting improvements in seizure frequency and in certain non-seizure outcomes associated with Epidiolex treatment. Further, the first presentation of data from the EpiCom trial, a prospective, interventional trial evaluating the impact of adjunctive Epidiolex on TSC-associated neuropsychiatric disorders (TAND), revealed improvements in behavioral symptom severity following treatment initiation.

JAZZ

Jazz Pharmaceuticals To Showcase New Real-World Evidence Reinforcing Epidiolex Benefits And Broad-Spectrum Efficacy In Treatment-Resistant Epilepsies At AES 2024 Annual Meeting

<h3>Gainers</h3>
<ul>
<li>Jeffs Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFBR#NASDAQ">JFBR</a>) stock increased by 38.6% to $3.19 during Friday's pre-market session. The company's market cap stands at $2.2 million. </li>
<li>Petco Health and Wellness (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WOOF#NASDAQ">WOOF</a>) stock moved upwards by 22.44% to $6.0. The market value of their outstanding shares is at $1.6 billion. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Color Star Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADD#NASDAQ">ADD</a>) shares rose 18.75% to $4.59. The market value of their outstanding shares is at $2.8 million. </li>
<li>American Outdoor Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AOUT#NASDAQ">AOUT</a>) stock moved upwards by 12.01% to $12.21. The market value of their outstanding shares is at $156.7 million. The company's, Q2 earnings came out yesterday. </li>
<li>Lululemon Athletica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) shares moved upwards by 10.19% to $379.97. The market value of their outstanding shares is at $46.6 billion. The company's, Q3 earnings came out yesterday. </li>
<li>Zumiez (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZUMZ#NASDAQ">ZUMZ</a>) stock increased by 9.17% to $22.01. The company's market cap stands at $421.3 million. As per the news, the Q3 earnings report came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Smith &amp; Wesson Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWBI#NASDAQ">SWBI</a>) stock declined by 16.7% to $11.35 during Friday's pre-market session. The company's market cap stands at $509.0 million. As per the news, the Q2 earnings report came out yesterday. </li>
<li>Latham Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWIM#NASDAQ">SWIM</a>) stock fell 15.89% to $5.4. The market value of their outstanding shares is at $624.3 million. </li>
<li>United Homes Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UHG#NASDAQ">UHG</a>) stock fell 15.74% to $5.14. The company's market cap stands at $248.8 million. </li>
<li>EpicQuest Education Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EEIQ#NASDAQ">EEIQ</a>) shares decreased by 8.92% to $0.92. The company's market cap stands at $11.9 million. </li>
<li>GigaCloud Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCT#NASDAQ">GCT</a>) shares declined by 8.7% to $22.15. The market value of their outstanding shares is at $907.5 million. </li>
<li>Shoe Carnival (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCVL#NASDAQ">SCVL</a>) shares fell 8.23% to $30.0. The market value of their outstanding shares is at $814.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AOUT

EEIQ

JFBR

LULU

SCVL

SWBI

SWIM

WOOF

ZUMZ

12 Consumer Discretionary Stocks Moving In Friday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) stock rose 192.4% to $3.07 during Friday's pre-market session. The market value of their outstanding shares is at $4.8 million. </li>
<li>VSee Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSEE#NASDAQ">VSEE</a>) shares moved upwards by 25.17% to $1.84. The market value of their outstanding shares is at $28.8 million. </li>
<li>Radiopharm Theranostics Limited - American Depositary Shares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RADX#NASDAQ">RADX</a>) shares increased by 24.5% to $22.0. </li>
<li>Innate Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPHA#NASDAQ">IPHA</a>) shares increased by 17.23% to $1.7. The market value of their outstanding shares is at $137.6 million. </li>
<li>Sonoma Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNOA#NASDAQ">SNOA</a>) stock increased by 14.28% to $2.96. The market value of their outstanding shares is at $3.9 million. </li>
<li>Cardio Diagnostics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDIO#NASDAQ">CDIO</a>) shares rose 14.12% to $0.53. The market value of their outstanding shares is at $21.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Bluejay Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJDX#NASDAQ">BJDX</a>) stock fell 25.3% to $4.63 during Friday's pre-market session. The market value of their outstanding shares is at $2.5 million. </li>
<li>Camp4 Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMP#NASDAQ">CAMP</a>) stock declined by 18.35% to $8.01. The market value of their outstanding shares is at $161.4 million. </li>
<li>Molecular Templates (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTEM#NASDAQ">MTEM</a>) shares fell 14.76% to $0.46. The market value of their outstanding shares is at $3.0 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) stock declined by 14.4% to $2.26. The company's market cap stands at $1.9 million. </li>
<li>Silexion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) shares declined by 11.62% to $2.74. The market value of their outstanding shares is at $4.3 million. </li>
<li>Virpax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) shares declined by 10.54% to $0.35. The market value of their outstanding shares is at $2.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BJDX

CAMP

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

IPHA

MTEM

RADX

SLXN

SNOA

VRPX

VSEE

12 Health Care Stocks Moving In Friday's Pre-Market Session

Gryphon Digital Mining, Inc. (GRYP) Q4 2023 Earnings Call Transcript

Gryphon Digital Mining, Inc. (GRYP) Q1 2024 Earnings Call Transcript

Gryphon Digital Mining, Inc. (GRYP) Q2 2024 Earnings Call Transcript

Gryphon Digital Mining, Inc. (GRYP) Q3 2024 Earnings Call Transcript

GRYP

KERNW

Press Releases

Akerna Announces Special Meeting Date to Vote on Merger with Gryphon Digital Mining, Inc.; Effectiveness of Registration Statement on Form S-4 in Connection with Merger

Akerna Corp. Announces Anticipated Closing of the Merger with Gryphon Digital Mining, Inc. and Reverse Stock Split

Markets

Gryphon Digital Mining Debuts on Nasdaq

KERN

Comments

Gryphon Digital Mining Inc Warrants (17/06/2024)

Gryphon Digital Mining Inc Warrants (17/06/2024) (KERNW) Forecast

Gryphon Digital Mining Inc Warrants (17/06/2024) (OTC:KERNW) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga